A HARTLEPOOL company has revealed plans for a massive £650,000 investment in its flourishing business – and more jobs.
Hart Biologicals, based on the Queens Meadow Business Park, is ploughing £150,000 into new equipment as well as spending £500,000 on buying the building it currently leases.
It is all part of a plan which will see staff numbers grow from 22 now to 30 in the next year and possibly higher in 2015.
The success of the firm, which makes biological reagents used to investigate blood clotting disorders, is It is all part of a plan which will see staff numbers grow from 22 now to 30 in the next year and possibly higher in 2015.
The success of the firm, which makes biological reagents used to investigate blood clotting disorders, is down to its expertise in a niche market.
Managing director Alby Pattison said: “Our contracts with our major company in Germany are growing significantly to the point where we have set up Hart Innovations which is a company within Hart Biologicals but it deals with research and development.”
The new firm will look at the management of bleeding in trauma and surgical fields.
Mr Pattison added: “We are now doing all the research and development for a company in Munich.”
But the good news goes even further as Hart Biologicals is also a key partner in a project which will develop a new blood analysis process - and that means the need to invest £150,000 in new manufacturing systems at the company’s Hartlepool headquarters.
Mr Pattison added: “The amount of money we have invested in the infrastructure meant it was in our interests to buy the building.”
The massive investment comes alongside a recruitment campaign. The first new arrivals will be on site today including a quality manager and stock controller, but it doesn’t end there.
Mr Pattison said: “We will be recruiting in 2014/2015 in manufacturing, research and development and quality control and we have taken on four apprentices from Hartlepool College of Further Education.
“We have tried to control our growth but growth is being driven by external influences, by people who want to work with us.”
He said Hart Biologicals has markets mainly in Germany, other parts of Europe and the USA, but potential markets were opening up in Asia, Russia and Brazil.
He added: “The North of England is developing into a powerhouse in the medical field.”
Hart Biologicals was first set up in 2002 and completed its first sale within a year from its then base on the Newburn Bridge Industrial Estate.
Mr Pattison said: “It was a very simple initial plan to give us enough to pay the key bills.”
But the company was soon flourishing and moved to its current 10,000ft state-of-the-art building in 2009.
Now, it is building more facilities to cope with demand. Mr Pattison said: “We are building two more labs and have just commissioned a new production line and that is to support a project with the German company.
“It will simplify the testing process tremendously and that should significantly improve hospital access to the machinery.”